
    
      This is a a dose and frequency (but not route of administration) blinded, prospective,
      randomized, dose-ranging study in patients with RRMS who have received natalizumab for at
      least 12 months according to the local prescribing guidelines. The study will explore dosing
      of natalizumab by subcutaneous and intravenous routes. Participants will be randomly assigned
      to 1 of 6 dosing regimens, blinded to natalizumab dose, but not route, for 60 weeks of
      treatment.
    
  